Legionfarm, pairing pro gamers with amateurs, raises $6 million Series A
15 May, 2021
– Alchemab Therapeutics from Cambridge, England, UK develops a platform that enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires.
– The company raised £60m in Series A funding.
– The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund.
– The new investment will be used to advance the company’s target-agnostic drug discovery platform.